

## TECHNO OFFER

### Antibiotic-associated adjuvant for multi-resistant bacteria (MRB) control

Calixarene – antibiotic – bacteria – MRB



#### CONTEXT

Bacteria that are frequently involved in the clinic may be resistant or even multi-resistant to antibiotics (MRB). The lack of new antibiotic solutions or new adjuvants sometimes leads patients to therapeutic dead-ends that can be fatal.

#### DESCRIPTION

The laboratory has shown that the combination of a calixarene with an antibiotic could give a new threshold of sensitivity to a bacterium resistant to this antibiotic.

This association tested with a large panel of antibiotics on three of the most dangerous MRB (*Pseudomonas aeruginosa*, *E. Coli* and *Streptococcus aureus* multi resistant) concludes that there is a synergy or additivity for some couples on these BMRs.

After having concluded in the non-toxicity of calixarene 1, in vivo investigations will be carried out on mice infected by *Pseudomonas aeruginosa* and on contaminated murine lungs.

#### competitive advantages

- New adjuvant in antibacterial control
- Synergistic or additive action
- Non-toxic in murine



#### markets and applications

Pharmaceutical



#### Stade de développement

TRL 3 in vitro studies



#### Intellectual property

Patent issued in 2013



#### Target partnership

patent licensing

#### CONTACT US

**Thomas BLUM**

Chargé de Développement

+33 (0)6 17 06 68 07



thomas.blum@sayens.fr